Defining the risks for cytomegalovirus infection and disease after solid organ transplantation

Pharmacotherapy

Volumn 30, Issue 2, 2010, Pages 144-157

  Stratta, Robert J ^a   Pietrangeli, Carolynn ^b   Baillie, G Mark ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b CTI Clinical Trial and Consulting Services   (United States)

Author keywords

Cytomegalovirus; Immunosuppression; Infection; Rejection; Risk factors; Serostatus; Solid organ transplantation

Indexed keywords

ALEMTUZUMAB; ANTIVIRUS AGENT; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; EVEROLIMUS; GANCICLOVIR; HYPERIMMUNE GLOBULIN; INTERLEUKIN 10; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1; MYCOPHENOLIC ACID; OKT 3; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; AGE DISTRIBUTION; ANEMIA; BLOOD TRANSFUSION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOMEGALOVIRUS INFECTION; DELAYED GRAFT FUNCTION; DIABETES MELLITUS; DONOR; GENETIC POLYMORPHISM; GENOTYPE; GRAFT RECIPIENT; GRAFT SURVIVAL; HIGH RISK PATIENT; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; INTESTINE TRANSPLANTATION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; LUNG TRANSPLANTATION; LYMPHOCYTOPENIA; MALNUTRITION; MANNOSE BINDING LECTIN DEFICIENCY; MIXED INFECTION; MONITORING; MORTALITY; MULTIPLE ORGAN FAILURE; NEUTROPENIA; ORGAN TRANSPLANTATION; PATIENT IDENTIFICATION; PROPHYLAXIS; PROTEIN DEFICIENCY; RACE; RETRANSPLANTATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTOPENIA; TREATMENT DURATION; UREMIA; VIRUS IMMUNITY; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; ORGAN TRANSPLANTATION; RISK ASSESSMENT; RISK FACTORS;

EID: 75849162995     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.2.144     Document Type: Review

References (129)

1. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007;357:2601-14.
2. Emery VC. Investigation of CMV disease in immunocompromised patients. J Clin Pathol 2001;54:84-8.
3. Kotton CN, Fishman JA. Viral infection in the renal transplant recipient. J Am Soc Nephrol 2005;16:1758-74.
4. Howell D, Miller S. Viral infections in solid organ transplants: hitting a moving target. Microsc Microanal 2005;11(suppl 2):966-7.
5. Schold JD, Rehman S, Kayler LK, Magliocca J, Srinivas TR, Meier-Kriesche HU. Treatment for BK virus: incidence, risk factors and outcomes for kidney transplant recipients in the United States. Transpl Int 2009;22:626-34.
6. Rubin RH. The pathogenesis and clinical management of cytomegalovirus infection in the organ transplant recipient: the end of the 'silo hypothesis.' Curr Opin Infect Dis 2007;20:399-407.
7. Razonable RR. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am J Health Syst Pharm 2005;62(8 suppl 1):S7-13.
8. Vamvakas EC. Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis. Transfus Med Rev 2005;19:181-99.
9. Schnitzler MA, Lowell JA, Hardinger KL, Boxerman SB, Bailey TC, Brennan DC. The association of cytomegalovirus sero-pairing with outcomes and costs following cadaveric renal transplantation prior to the introduction of oral ganciclovir CMV prophylaxis. Am J Transplant 2003;3: 445-51.
10. Hartmann A, Sagedal S, Hjelmesaeth J. The natural course of cytomegalovirus infection and disease in renal transplant recipients. Transplantation 2006;82(2 suppl):S15-17.
11. Razonable R, Paya C. Beta-herpesviruses in transplantation. Rev Med Microbiol 2002;13:163-76.
12. Kedhar SR, Jabs DA. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Herpes 2007;14:66-71.
13. Emory V. Facing the facts: the indirect effects of cytomegalovirus. Transplantation 2007;84(suppl 6):S7-10.
14. Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA 1989;261: 3607-9.
15. Nordoy I, Muller F, Nordal KP, et al. The role of the tumor necrosis factor system and interleukin-10 during cytomegalovirus infection in renal transplant recipients. J Infect Dis 2000;181:51-7.
16. Kas-Deelen AM, de Maar EF, Harmsen MC, Driessen C, van Son WJ, The TH. Uninfected and cytomegalic endothelial cells in blood during cytomegalovirus infection: effect of acute rejection. J Infect Dis 2000;181:721-4.
17. Grefte A, van der Giessen M, van Son W, The TH. Circulating cytomegalovirus (CMV)-infected endothelial cells in patients with an active CMV infection. J Infect Dis 1993;167:270-7.
18. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004;66:329-37.
19. Sagedal S, Rollag H, Hartmann A. Cytomegalovirus infection in renal transplant recipients is associated with impaired survival irrespective of expected mortality risk. Clin Transplant 2007;21:309-13.
20. Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008;46:840-6.
21. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008;8:975-83.
22. Pescovitz MD. Benefits of cytomegalovirus prophylaxis in solid organ transplantation. Transplantation 2006;82(2 suppl):S4-8.
23. Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver Transpl 2007;13:1703-9.
24. Husain S, Pietrangeli CE, Zeevi A. Delayed onset CMV disease in solid organ transplant recipients. Transpl Immunol 2009;21:1-9.
25. Boeckh M, Riddell SR. Immunologic predictors of late cytomegalovirus disease after solid organ transplantation: an elusive goal? J Infect Dis 2007;195:615-17.
26. Shibolet O, Ilan Y, Kalish Y, et al. Late cytomegalovirus disease following liver transplantation. Transpl Int 2003;16: 861-5.
27. Shibolet O, Ilan Y, Kalish Y, et al. Late cytomegalovirus infection occurring two or more years following liver transplantation: a report of seven cases and review of the literature. Transplant Proc 2003;35:663-4.
28. Slifkin M, Tempesti P, Poutsiaka DD, Snydman DR. Late and atypical cytomegalovirus disease in solid-organ transplant recipients. Clin Infect Dis 2001;33:E62-8.
29. Cummings NW, Deziel PJ, Abrahamn RS, Razonable RR. Deficiency of cytomegalovirus (CMV)-specific CD8+ T cells in patients presenting with late-onset CMV disease several years after transplantation. Transplant Infect Dis 2009;11: 20-7.
30. Balfour HH Jr, Chace BA, Stapleton JT, Simmons RL, Fryd DS. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989;320:1381-7.
31. Gane E, Saliba F, Valdecasas GJ, et al, for the Oral Ganciclovir International Transplantation Study Group. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 1997;350:1729-33. (Erratum in Lancet 1998;351:454.)
32. Lowance D, Neumayer HH, Legendre CM, et al, for the International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999;340:1462-70.
33. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004;4:611-20.
34. Razonable RR, Rivero A, Rodriguez A, et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001;184:1461-4.
35. American Society of Transplantation, Infectious Disease Community of Practice. Cytomegalovirus. Am J Transplant 2004;4(suppl 10):51-8.
36. Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian Society of Transplantation consensus workshop on cytomegalovirus management in solid organ transplantation: final report. Am J Transplant 2005;5:218-27.
37. British Transplant Society. Guidelines for the prevention and management of cytomegalovirus disease after solid organ transplantation, 2nd ed. London: British Transplant Society; 2004.
38. Razonable RR, Emery VC. Management of CMV infection and disease in transplant patients: 27-29 February 2004. Herpes 2004;11:77-86.
39. Rayes N, Seehofer D, Lullius SG, et al. Monitoring of human cytomegalovirus, HHV-6 and HHV-7 infection in kidney transplant recipients by molecular methods to predict HCMV disease after transplantation: a prospective study. Ann Transplant 2005;10:23-8.
40. Stratta RJ, Alloway RR, Lo A, Hodge EE. Effect of donor-recipient cytomegalovirus serologic status on outcomes in simultaneous kidney-pancreas transplant recipients. Transplant Proc 2004;36:1082-3.
41. Stratta RJ, Thacker LR, Sundberg AK. Multivariate analysis of the influence of donor and recipient cytomegalovirus seropairing on outcomes in simultaneous kidney-pancreas transplantation: the south-eastern organ procurement foundation experience. Transplant Proc 2005;37:1271-3.
42. Bonaros N, Mayer B, Schachner T, Laufer G, Kocher A. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis. Clin Transplant 2008;22:89-97.
43. Snydman DR. Historical overview of the use of cytomegalovirus hyperimmune globulin in organ transplantation. Transpl Infect Dis 2001;3(suppl 2):6-13.
44. Weill D, Lock BJ, Wewers DL, et al. Combination prophylaxis with ganciclovir and cytomegalovirus (CMV) immune globulin after lung transplantation: effective CMV prevention following daclizumab induction. Am J Transplant 2003;3: 492-6.
45. Kocher AA, Bonaros N, Dunkler D, et al. Long-term results of CMV hyperimmune globulin prophylaxis in 377 heart transplant recipients. J Heart Lung Transplant 2003;22:250-7.
46. Humar A, Mazzulli T, Moussa G, et al. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. Am J Transplant 2005;5:1065-70.
47. Kijpittayarit S, Deziel P, Eid AJ, Razonable RR. Primary cytomegalovirus disease after five years of antiviral prophylaxis. Transplantation 2006;81:137-8.
48. Kaufman DB, Leventhal JR, Gallon LG, et al. Risk factors and impact of cytomegalovirus disease in simultaneous pancreas-kidney transplantation. Transplantation 2001;72: 1940-5.
49. Zamora MR. Cytomegalovirus and lung transplantation. Am J Transplant 2004;4:1219-26.
50. Hughes D, Hafferty J, Fulton L, et al. Donor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patients. J Clin Virol 2008;41:92-5.
51. Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995;86:3598-603.
52. Preiksaitis JK. The cytomegalovirus-"safe" blood product: is leukoreduction equivalent to antibody screening? Transfus Med Rev 2000;14:112-36.
53. Jacobson MA, Sinclair E, Bredt B, et al. Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12. Vaccine 2006;24:5311-19.
54. Gonczol E, Plotkin S. Development of a cytomegalovirus vaccine: lessons from recent clinical trials. Expert Opin Biol Ther 2001;1:401-12.
55. Pass RF, Zhang C, Evans A, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 2009;360: 1191-9.
56. Dekker CL, Arvin AM. One step closer to a CMV vaccine. N Engl J Med 2009;360:1250-2.
57. Razonable RR, van Cruijsen H, Brown RA, et al. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. J Infect Dis 2003;187:1801-8.
58. Boeckh M, Boivin G. Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin Microbiol Rev 1998;11:533-54.
59. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000;355:2032-6.
60. Mattes FM, Hainsworth EG, Geretti AM, et al. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. J Infect Dis 2004;189:1355-61.
61. Helantera I, Koskinen P, Finne P, et al. Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survival. Transpl Int 2006;19: 893-900.
62. Kondo K, Kaneshima H, Mocarski ES. Human cytomegalovirus latent infection of granulocyte-macrophage progenitors. Proc Natl Acad Sci USA 1994;91:11879-83.
63. Paya C, Razonable RR. Cytomegalovirus infection after solid organ transplantation. In: Transplant infections, 2nd ed. Philadelphia: Lippincott, Williams and Wilkins; 2003:298-325.
64. Duncan AJ, Dummer JS, Paradis IL, et al. Cytomegalovirus infection and survival in lung transplant recipients. J Heart Lung Transplant 1991;10(5 pt 1):638-46.
65. Becker BN, Becker YT, Leverson GE, Simmons WD, Sollinger HW, Pirsch JD. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation. Am J Kidney Dis 2002;39:1088-95.
66. Axelrod D, Leventhal JR, Gallon LG, Parker MA, Kaufman DB. Reduction of CMV disease with steroid-free immunosuppression in simultaneous pancreas-kidney transplant recipients. Am J Transplant 2005;5:1423-9.
67. Drew WL, Roback JD. Prevention of transfusion-transmitted cytomegalovirus: reactivation of the debate? Transfusion 2007;47:1955-8.
68. Laupacis A, Brown J, Costello B, et al. Prevention of posttransfusion CMV in the era of universal WBC reduction: a consensus statement. Transfusion 2001;41:560-9.
69. Preiksaitis JK, Desai S, Vaudry W, et al. Transfusion- and community-acquired cytomegalovirus infection in children with malignant disease: a prospective study. Transfusion 1997;37:941-6.
70. Ljungman P. Risk of cytomegalovirus transmission by blood products to immunocompromised patients and means for reduction. Br J Haematol 2004;125:107-16.
71. Zeevi A, Husain S, Spichty KJ, et al. Recovery of functional memory T cells in lung transplant recipients following induction therapy with alemtuzumab. Am J Transplant 2007;7:471-5.
72. Zeevi A, Morel P, Spichty K, et al. Clinical significance of CMV-specific T helper responses in lung transplant recipients. Hum Immunol 1998;59:768-75.
73. Gamadia LE, Remmerswaal EB, Weel JF, Bemelman F, van Lier RA, Ten Berge IJ. Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood 2003;101:2686-92.
74. Kumar D, Chernenko S, Moussa G, et al. A prospective study of CD8+ T-cell-mediated immunity to cytomegalovirus (CMV) as a predictor of CMV disease [abstract]. Am J Transplant 2008;8(suppl 2):266.
75. Westall GP, Mifsud NA, Kotsimbos T. Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity. Am J Transplant 2008;8:1749-54.
76. Kowalski RJ, Post DR, Mannon RB, et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 2006;82:663-8.
77. Doxiadis II, Smits JM, Schreuder GM, et al. Association between specific HLA combinations and probability of kidney allograft loss: the taboo concept. Lancet 1996;348:850-3.
78. Demopoulos L, Polinsky M, Steele G, et al. Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials. Transplant Proc 2008;40:1407-10.
79. Department of Health and Human Services, United Network for Organ Sharing, and Scientific Registry of Transplant Recipients. The 2007 annual report of the U.S. organ procurement and transplantation network and the scientific registry of transplant recipients: transplant data 1996-2007. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; Richmond, VA: United Network for Organ Sharing; Ann Arbor, MI: University Renal Research and Education Association; 2008.
80. Ciancio G, Burke GW III. Alemtuzumab (Campath-1H) in kidney transplantation. Am J Transplant 2008;8:15-20.
81. Magliocca JF, Odorico JS, Pirsch JD, et al. A comparison of alemtuzumab with basiliximab induction in simultaneous pancreas-kidney transplantation. Am J Transplant 2008;8: 1702-10.
82. Huurman VA, Kalpoe JS, van de Linde P, et al. Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients. Diabetes Care 2006;29:842-7.
83. Kaufman DB, Burke GW III, Bruce DS, et al. Prospective, randomized, multi-center trial of antibody induction therapy in simultaneous pancreas-kidney transplantation. Am J Transplant 2003;3:855-64.
84. Burke GW III, Kaufman DB, Millis JM, et al. Prospective, randomized trial of the effect of antibody induction in simultaneous pancreas and kidney transplantation: three-year results. Transplantation 2004;77:1269-75.
85. Docke WD, Prosch S, Fietze E, et al. Cytomegalovirus reactivation and tumour necrosis factor. Lancet 1994;343: 268-9.
86. Fietze E, Prosch S, Reinke P, et al. Cytomegalovirus infection in transplant recipients: the role of tumor necrosis factor. Transplantation 1994;58:675-80.
87. Kaden J. Eleven years intraoperative ATG bolus: a list of successes. Ann Transplant 2002;7:4-10.
88. Kaden J, Eichler S, May G, Strobelt V. The ATG bolus does not induce a persistent inversion of the CD4/8 ratio. Transplant Proc 2002;34:2379-81.
89. Baez Y, Giron F, Nino-Murcia A, Rodriguez J, Salcedo S. Experience with alemtuzumab (Campath-1H) as induction agent in renal transplantation followed by steroid-free immunosuppression. Transplant Proc 2008;40:697-9.
90. Muthusamy AS, Vaidya AC, Sinha S, Roy D, Elker DE, Friend PJ. Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation. Am J Transplant 2008;8:2126-31.
91. San Juan R, Aguado JM, Lumbreras C, et al. Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation. Clin Infect Dis 2008;47:875-82.
92. Cainelli F, Vento S. Infections and solid organ transplant rejection: a cause-and-effect relationship? Lancet Infect Dis 2002;2:539-49.
93. Sagedal S, Nordal KP, Hartmann A, et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002;2:850-6.
94. Dmitrienko S, Balshaw R, Machnicki G, Shapiro RJ, Keown PA. Probabilistic modeling of cytomegalovirus infection under consensus clinical management guidelines. Transplantation 2009;87:570-7.
95. Fehr T, Sykes M. Clinical experience with mixed chimerism to induce transplantation tolerance. Transpl Int 2008;21: 1118-35.
96. Rana A, Robles S, Russo MJ, et al. The combined organ effect: protection against rejection? Ann Surg 2008;248: 871-9.
97. Zeevi A, Spichty K, Banas R, et al. Clinical significance of cytomegalovirus-specific T helper responses and cytokine production in lung transplant recipients. Intervirology 1999;42:291-300.
98. Portela D, Patel R, Larson-Keller JJ, et al. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation. J Infect Dis 1995;171:1014-18.
99. Oh CS, Stratta RJ, Fox BC, Sollinger HW, Belzer FO, Maki DG. Increased infections associated with the use of OKT3 for treatment of steroid-resistant rejection in renal transplantation. Transplantation 1988;45:68-73.
100. Kidd IM, Clark DA, Sabin CA, et al. Prospective study of human beta-herpesviruses after renal transplantation: association of human herpesvirus 7 and cytomegalovirus coinfection with cytomegalovirus disease and increased rejection. Transplantation 2000;69:2400-4.
101. O'Grady JG, Alexander GJ, Sutherland S, et al. Cytomegalovirus infection and donor/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bileduct syndrome after liver transplantation. Lancet 1988;2: 302-5.
102. Freeman RB, Paya C, Pescovitz MD, et al. Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. Transplantation 2004;78:1765-73.
103. Lautenschlager I, Lappalainen M, Linnavuori K, Suni J, Hockerstedt K. CMV infection is usually associated with concurrent HHV-6 and HHV-7 antigenemia in liver transplant patients. J Clin Virol 2002;25(suppl 2):S57-61.
104. Akalin E, Sehgal V, Ames S, et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 2003;3:731-5.
105. Snydman DR. The case for cytomegalovirus prophylaxis in solid organ transplantation. Rev Med Virol 2006;16:289-95.
106. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002;34:1094-7.
107. Coaquette A, Bourgeois A, Dirand C, Varin A, Chen W, Herbein G. Mixed cytomegalovirus glycoprotein B genotypes in immunocompromised patients. Clin Infect Dis 2004;39:155-61.
108. Snydman DR. Counterpoint: prevention of cytomegalovirus (CMV) infection and CMV disease in recipients of solid organ transplants: the case for prophylaxis. Clin Infect Dis 2005;40: 709-12.
109. Singh N. Optimal prevention of late-onset cytomegalovirus (CMV) disease and other sequelae of CMV infection in organ transplant recipients. Clin Infect Dis 2008;47:296-7.
110. Baillie GM. Prevention of cytomegalovirus disease in solid organ transplant patients: prophylactic versus preemptive therapy. Am J Health Syst Pharm 2006;63(19 suppl 5):S10-16.
111. Small LN, Lau J, Snydman DR. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006;43:869-80.
112. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005;365: 2105-15.
113. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Metaanalysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005;143:870-80.
114. Strippoli GF, Hodson EM, Jones C, Craig JC. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation 2006;81:139-45.
115. Falagas ME, Paya C, Ruthazer R, et al. Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation: a prospective derivation and validation cohort analysis. Transplantation 1998;66:1020-8.
116. Falagas ME, Snydman DR, Ruthazer R, et al, for the Boston Center for Liver Transplantation CMVIG Study Group. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. Clin Transplant 1997;11(5 pt 1):432-7.
117. Paya CV. Economic impact of cytomegalovirus in solid organ transplantation. Transpl Infect Dis 2001;3(suppl 2):14-19.
118. Oppenheimer F, Gonzalez-Molina M, Rubio M. Cost of prophylaxis in the management of cytomegalovirus infection in solid organ transplant recipients. Clin Transplant 2007;21:441-8.
119. Potena L, Holweg CT, Chin C, et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation 2006;82:398-405.
120. Potena L, Valantine HA. Cytomegalovirus-associated allograft rejection in heart transplant patients. Curr Opin Infect Dis 2007;20:425-31.
121. Avery RK. Management of late, recurrent, and resistant cytomegalovirus in transplant patients. Transplant Rev 2007;21:65-76.
122. Legendre C, Pascual M. Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences. Clin Infect Dis 2008;46:732-40.
123. Limaye AP, Bakthavatsalam R, Kim HW, et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006;81:1645-52.
124. Doyle AM, Warburton KM, Goral S, Blumberg E, Grossman RA, Bloom RD. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course. Transplantation 2006;81:1106-11.
125. Walker JK, Scholz LM, Scheetz MH, et al. Leukopenia complicates cytomegalovirus prevention after renal transplantation with alemtuzumab induction. Transplantation 2007;83: 874-82.
126. Randolph-Habecker J, Iwata M, Torok-Storb B. Cytomegalovirus mediated myelosuppression. J Clin Virol 2002;25(suppl 2):S51-6.
127. Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant 2008;22:162-70.
128. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000;356: 645-9.
129. Humar A, Kumar D, Boivin G, Caliendo AM. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 2002;186:829-33.